Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)

BACKGROUND: In the PACIFIC study, progression-free survival (PFS) and overall survival (OS) of patients with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) were prolonged by durvalumab as maintenance therapy after radical concurrent chemoradiotherapy using platinum-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Tadaaki, Uchino, Junji, Chihara, Yusuke, Shimamoto, Takayuki, Iwasaku, Masahiro, Tamiya, Nobuyo, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268142/
https://www.ncbi.nlm.nih.gov/pubmed/32536981
http://dx.doi.org/10.1177/1758835920927841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268142/
https://www.ncbi.nlm.nih.gov/pubmed/32536981
http://dx.doi.org/10.1177/1758835920927841

Ejemplares similares